CSF Aβ(42) and tau in Parkinson's disease with cognitive impairment.
We tested the hypothesis that the CSF biomarker signature associated with Alzheimer's disease (AD) is present in a subset of individuals with Parkinson's disease and Dementia (PD-D) or with PD and Cognitive Impairment, Not Dementia (PD-CIND). We quantified CSF Aβ(42), total tau (T-tau), and phospho-tau (P181-tau) using commercially available kits. Samples were from 345 individuals in seven groups (n): Controls ≤50 years (35), Controls >50 years (115), amnestic Mild Cognitive Impairment (aMCI) (24), AD (49), PD (49), PD-CIND (62), and PD-D (11). We observed expected changes in AD or aMCI compared with age-matched or younger controls. CSF Aβ(42) was reduced in PD-CIND (P < 0.05) and PD-D (P < 0.01), whereas average CSF T-tau and P181-tau were unchanged or decreased. One-third of PD-CIND and one-half of PD-D patients had the biomarker signature of AD. Abnormal metabolism of Aβ(42) may be a common feature of PD-CIND and PD-D.
Montine
Thomas J
TJ
Department of Pathology, University of Washington School of Medicine, Seattle, Washington 98104, USA.
Shi
Min
M
Quinn
Joseph F
JF
Peskind
Elaine R
ER
Craft
Suzanne
S
Ginghina
Carmen
C
Chung
Kathryn A
KA
Kim
Hojoong
H
Galasko
Douglas R
DR
Jankovic
Joseph
J
Zabetian
Cyrus P
CP
Leverenz
James B
JB
Zhang
Jing
J
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D016229:Amyloid beta-Peptides / Q000134:cerebrospinal fluid*; D015415:Biomarkers / Q000134:cerebrospinal fluid; D003072:Cognition Disorders / Q000134:cerebrospinal fluid*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010300:Parkinson Disease / Q000134:cerebrospinal fluid*; D010446:Peptide Fragments / Q000134:cerebrospinal fluid*; D016875:tau Proteins / Q000134:cerebrospinal fluid*
D016229:Amyloid beta-Peptides; D015415:Biomarkers; D010446:Peptide Fragments; C075222:amyloid beta-protein (1-42); D016875:tau Proteins
Biol Psychiatry. 2008 Nov 15;64(10):850-5
18395699
J Neurol Neurosurg Psychiatry. 1988 Jun;51(6):745-52
2841426
Lancet Neurol. 2008 Aug;7(8):704-14
18635019
Neurology. 2009 Jul 28;73(4):294-301
19636049
Mov Disord. 2009 Nov 15;24(15):2203-10
19795497
Neurology. 1984 Jul;34(7):939-44
6610841
Am J Clin Pathol. 2008 Apr;129(4):526-9
18343778
Mov Disord. 2007 Sep 15;22(12):1689-707; quiz 1837
17542011
Arch Neurol. 2009 Dec;66(12):1557-62
20008664
Neurology. 1993 Nov;43(11):2412-4
8232972
Arch Neurol. 2007 Mar;64(3):343-9
17210801
J Intern Med. 2004 Sep;256(3):183-94
15324362
J Neurol Sci. 2010 Feb 15;289(1-2):18-22
19733364
EMBO Mol Med. 2009 Nov;1(8-9):371-80
20049742
Neurology. 2007 Aug 14;69(7):631-9
17698783
Ann Neurol. 2009 Apr;65(4):403-13
19296504
Brain. 2010 Mar;133(Pt 3):713-26
20157014
JAMA. 2009 Jul 22;302(4):385-93
19622817
Neurology. 2010 Jan 5;74(1):77-84
20038776